Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes
Listen to this summary
The authors aimed to characterize the immunological landscape of different basal cell carcinoma (BCC) subtypes by examining PD-L1, dendritic cells, and HLA expression through immunohistochemistry. Their findings revealed that while PD-L1 was not expressed on BCC tumor cells, it was present on immune cells, particularly in basosquamous BCCs, suggesting that this subtype may be more responsive to anti-PD-1 therapy than others. Overall, the study highlights the immune-privileged status of BCC and challenges existing notions regarding PD-L1 expression in these tumors.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Journal of cutaneous pathology
View all →Jun 9, 2026 · Journal of cutaneous pathology
TFG-Containing Fusions in Melanocytic Tumors: From Polymorphic Read-Through Transcripts to Oncogenic Kinase Fusions
Jun 7, 2026 · Journal of cutaneous pathology
Dermatofibroma Hypocellularity Is Associated With Patient Age: A Retrospective Study of 307 Cases
More in Dermatology
View all →Nov 19, 2026 · Lancet (London, England)
Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.
Nov 19, 2026 · Lancet (London, England)
Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).
Nov 19, 2026 · Lancet (London, England)
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.
Nov 19, 2026 · The New England journal of medicine
Assessing Multiple Treatment Regimens for Tuberculosis.
Nov 18, 2026 · The New England journal of medicine
Acute Respiratory Distress Syndrome.
Nov 17, 2026 · Lancet (London, England)
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


